BR112014014960A2 - métodos para o diagnóstico da doença de alzheimer - Google Patents

métodos para o diagnóstico da doença de alzheimer

Info

Publication number
BR112014014960A2
BR112014014960A2 BR112014014960A BR112014014960A BR112014014960A2 BR 112014014960 A2 BR112014014960 A2 BR 112014014960A2 BR 112014014960 A BR112014014960 A BR 112014014960A BR 112014014960 A BR112014014960 A BR 112014014960A BR 112014014960 A2 BR112014014960 A2 BR 112014014960A2
Authority
BR
Brazil
Prior art keywords
methods
disease
abstract
diagnosing
amyloidosis
Prior art date
Application number
BR112014014960A
Other languages
English (en)
Inventor
Holtzman David
Bateman Randall
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of BR112014014960A2 publication Critical patent/BR112014014960A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

abstract: front page image (en)the present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for aß amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. methods of measuring the in vivo metabolism of biomolecules produced in the cns in a subject are provided. tradução do resumo resumo patente de invenção: "métodos para o diagnóstico da doença de alzheimer". a presente invenção refere-se aos métodos de diagnóstico, mo-nitoramento e avaliação dos efeitos de tratamento para a aß amiloidose, no início do curso da doença clínica ou antes do começo das lesões cerebrais e sintomas clínicos. os métodos de medição do metabolismo in vivo das bio-moléculas produzidas no cns em um indivíduo são fornecidos.
BR112014014960A 2011-12-19 2012-12-19 métodos para o diagnóstico da doença de alzheimer BR112014014960A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577439P 2011-12-19 2011-12-19
PCT/US2012/070623 WO2013096451A2 (en) 2011-12-19 2012-12-19 Methods for diagnosing alzheimer's disease

Publications (1)

Publication Number Publication Date
BR112014014960A2 true BR112014014960A2 (pt) 2017-06-13

Family

ID=48669694

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014960A BR112014014960A2 (pt) 2011-12-19 2012-12-19 métodos para o diagnóstico da doença de alzheimer

Country Status (8)

Country Link
US (2) US20140370619A1 (pt)
EP (1) EP2795325B9 (pt)
JP (1) JP6129868B2 (pt)
AU (1) AU2012359020B2 (pt)
BR (1) BR112014014960A2 (pt)
CA (1) CA2859808A1 (pt)
WO (1) WO2013096451A2 (pt)
ZA (1) ZA201404500B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6759104B2 (ja) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
EP3783364A3 (en) * 2014-05-22 2021-05-19 Shimadzu Corporation Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
EP3175242A4 (en) 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
US10830775B2 (en) 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
WO2017047529A1 (ja) * 2015-09-16 2017-03-23 株式会社 島津製作所 脳内のアミロイドβ蓄積状態を評価するマルチプレックスバイオマーカー及びその分析方法
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
US11360098B2 (en) * 2015-09-28 2022-06-14 Quest Diagnostics Investments Llc Amyloid beta detection by mass spectrometry
CN109863395B (zh) 2016-09-07 2023-05-23 梅约医学教育与研究基金会 分子量法鉴定和监测裂解免疫球蛋白
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483399B1 (en) * 2002-02-12 2008-10-29 The Regents of the University of California Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products
WO2006107814A2 (en) * 2005-04-06 2006-10-12 Washington University In St. Louis Methods for measuring the metabolism of neurally derived biomolecules in vivo
US20110143380A1 (en) * 2006-03-14 2011-06-16 The Washington University Alzheimer's disease biomarkers and methods of use
US8673579B2 (en) * 2006-07-28 2014-03-18 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US20090142766A1 (en) * 2007-11-09 2009-06-04 Washington University In St. Louis Methods for measuring the metabolism of cns derived biomolecules in vivo
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method
US20130115716A1 (en) * 2010-05-24 2013-05-09 The Washington University Methods of determining amyloid beta turnover in blood

Also Published As

Publication number Publication date
US20160169916A1 (en) 2016-06-16
ZA201404500B (en) 2017-09-27
JP2015505365A (ja) 2015-02-19
AU2012359020A1 (en) 2014-07-10
US20140370619A1 (en) 2014-12-18
AU2012359020B2 (en) 2017-04-13
WO2013096451A2 (en) 2013-06-27
WO2013096451A3 (en) 2014-09-25
EP2795325B1 (en) 2017-09-13
JP6129868B2 (ja) 2017-05-17
EP2795325A4 (en) 2016-02-17
EP2795325B9 (en) 2017-11-15
CA2859808A1 (en) 2013-06-27
EP2795325A2 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
ECSP13012609A (es) Composición farmacéutica
MX349711B (es) Método óptico para la detección de la enfermedad de alzheimer.
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
BR112013022493A2 (pt) equipamento e método para examinar, diagnosticar ou auxiliar no diagnóstico e no tratamento de problemas funcionais de visão
MY164579A (en) Safe and functional humanized antibodies
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
WO2013128293A3 (en) Methods, apparatuses and systems for diagnosis and treatment of mood disorders
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
CO6450654A2 (es) Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas
BRPI1014595A2 (pt) procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer
WO2013011294A3 (en) Diagnosis of alzheimer's disease
WO2015034886A3 (en) Wellness panel for companion animals
BR112015014232A2 (pt) lesão renal aguda
EP2509488A4 (en) METHODS AND ARRANGEMENTS FOR THE ANALYSIS, DIAGNOSIS AND MONITORING OF VOCAL STRENGTH PROCESSING BY OPTICAL COHERENCE TOMOGRAPHY
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
IN2014DN08398A (pt)
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
BR112015027249A2 (pt) método de diagnóstico de câncer
WO2014117680A3 (zh) 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆
WO2013064702A3 (en) Probes for diagnosis and monitoring of neurodegenerative disease
EP2990801A4 (en) DIAGNOSIS DIAGNOSIS FOR THE DIAGNOSIS OF DISORDER OR DISEASE IN CONNECTION WITH ABNORMAL PROTEIN AGGREGATION OR ERRORS BY RESOLUTION OF PROTEIN AGGREGATES
BR112015021507A8 (pt) métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]